对多巴胺受体-连接体相互作用的结构洞察:从激动剂到对抗剂
bioRxiv : the preprint server for biology
|November 14, 2023
概括
这项研究揭示了罗提古丁如何与多巴胺D1和D5受体结合. 它还详细介绍了对抗剂的结合和稳定性,为开发新中枢神经系统疾病治疗提供了洞察力.
科学领域:
- 神经药理学神经药理学
- 分子生物学分子生物学
- 计算化学是一种计算化学.
背景情况:
- 多巴胺受体 (D1R和D5R) 是中枢神经系统 (CNS) 疾病的关键标.
- 了解连接体相互作用是开发有效治疗方法的关键.
研究的目的:
- 为了研究在多巴胺D1和D5受体上的配体的结合方式和稳定性.
- 探索对抗剂与这些受体结合的结构和能量基础.
主要方法:
- 使用了分子建模和计算模拟.
- 分析了联结体-受体相互作用.
- 进行了热稳定性测试,以评估结合稳定性.
主要成果:
- 在D1R和D5R的正经结合口袋 (OBP) 确定了泛激素罗提古丁的通用结合模式.
- 分析了对抗剂-受体复合体 (SKF83566,SCH23390) 的稳定性.
- 突变对联体受体相互作用和结合稳定性的影响得到了阐明.
结论:
- 该研究提供了对多巴胺受体药理学的详细见解.
- 这些发现提高了对连接体结合机制的理解.
- 这项研究支持未来的中枢神经系统疾病药物开发.
相关概念视频
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Drug-Receptor Interactions
5.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.3K
Drug-Receptor Interaction: Antagonist
3.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
3.0K
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Opioid Receptors: Overview
932
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
932


